Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M504432200 on August 9, 2005 Originally published In Press as doi:10.1074/jbc.M504432200 on July 28, 2005

J. Biol. Chem., Vol. 280, Issue 37, 32107-32114, September 16, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/37/32107    most recent
M504432200v2
M504432200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santiago-Walker, A. E.
Right arrow Articles by Meinkoth, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santiago-Walker, A. E.
Right arrow Articles by Meinkoth, J. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Protein Kinase C {delta} Stimulates Apoptosis by Initiating G1 Phase Cell Cycle Progression and S Phase Arrest*

Ademi E. Santiago-Walker{ddagger}1, Aphrothiti J. Fikaris{ddagger}, Gary D. Kao§, Eric J. Brown¶, Marcelo G. Kazanietz{ddagger}, and Judy L. Meinkoth{ddagger}2

From the Departments of {ddagger}Pharmacology, §Radiation Oncology, and Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6061

Received for publication, April 22, 2005 , and in revised form, July 25, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Overexpression of protein kinase C {delta} (PKC{delta}) stimulates apoptosis in a wide variety of cell types through a mechanism that is incompletely understood. PKC{delta}-deficient cells are impaired in their response to DNA damage-induced apoptosis, suggesting that PKC{delta} is required to mount an appropriate apoptotic response under conditions of stress. The mechanism through which it does so remains elusive. In addition to effects on cell survival, PKC{delta} elicits pleiotropic effects on cellular proliferation. We now provide the first evidence that the ability of PKC{delta} to stimulate apoptosis is intimately linked to its ability to stimulate G1 phase cell cycle progression. Using an adenoviral-based expression system to express PKC{alpha},-{delta}, and -{epsilon} in epithelial cells, we demonstrate that a modest increase in PKC{delta} activity selectively stimulates quiescent cells to initiate G1 phase cell cycle progression. Rather than completing the cell cycle, PKC{delta}-infected cells arrest in S phase, an event that triggers caspase-dependent apoptotic cell death. Apoptosis was preceded by the activation of cell cycle checkpoints, culminating in the phosphorylation of Chk-1 and p53. Strikingly, blockade of S phase entry using the phosphatidylinositol 3-kinase inhibitor LY294002 prevented checkpoint activation and apoptosis. In contrast, inhibitors of mitogen-activated protein kinase cascades failed to prevent apoptosis. These findings demonstrate that the biological effects of PKC{delta} can be extended to include positive regulation of G1 phase cell cycle progression. Importantly, they reveal the existence of a novel, cell cycle-dependent mechanism through which PKC{delta} stimulates cell death.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein kinase C (PKC)3 is a family of serine/threonine protein kinases composed of three subclasses consisting of the classical ({alpha}, {beta}I, {beta}II, and {gamma}), novel ({delta}, {epsilon}, {eta}, and {theta}), and atypical ({zeta} and {iota}/{lambda}) PKC isoforms. PKC isoforms differ in their requirement for calcium and their responsiveness to the lipid second messenger diacylglycerol. The classical (calcium-dependent) and novel (calcium-independent) isoforms are responsive to diacylglycerol, whereas the atypical isoforms are diacylglycerol-insensitive (reviewed in Ref. 1). Most cells express multiple PKC isozymes that require distinct cofactors and exhibit unique intracellular localizations. Pharmacological inhibitors have been used to assess the roles of individual PKC isozymes. Much of what is known regarding the biological roles of PKC{delta} has been derived from studies using the PKC{delta}-selective inhibitor rottlerin, the specificity of which is in question. The isolation of cell lines overexpressing or lacking individual isozymes has been used to decipher the physiological roles of select PKC isozymes. A major limitation of this approach is that it does not readily distinguish between the effects of PKC activation versus the subsequent down-regulation of PKC expression. We opted to use adenoviruses to drive selective, modest increases in the activities of PKC{alpha},-{delta}, and -{epsilon}, a powerful approach that has provided substantial insight into the regulation of cellular survival by PKC (2–4). We selected thyroid epithelial cells for this analysis because alterations in PKC activity, expression, and structure (5–9) have been documented in human thyroid tumors. The results of this analysis revealed the existence of a novel mechanism through which PKC{delta} stimulates apoptosis and demonstrate a tight linkage between the effects of PKC{delta} on cell proliferation and cell death.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—The following antibodies were used: active caspase-3 (Asp-175), caspase-3 (Cell Signaling, Beverly, MA), phospho-H2AX (Ser-139) (Upstate, Charlottesville, VA), phospho-p53 (Ser-15) (Cell Signaling, Beverly, MA), phospho-Chk1 (Ser-345) (Cell Signaling), cyclins A (C-19), and E (M-20) (Santa Cruz Biotechnology, Santa Cruz, CA), cyclin B1 (Cell Signaling), nPKC{delta} (C-20) (Santa Cruz Biotechnology), Cdk-2 (M2) (Santa Cruz Biotechnology). LY294002 and SB203580 were purchased from Sigma. Q-VD-OPh (QVD) and GF109203X were from Calbiochem (EMD Biosciences, La Jolla, CA). SP600125 was from Alexis Biochemicals (Lausen, Switzerland), and UO126 was from Promega (Madison, WI).

Cell Culture—Wistar rat thyroid cells were propagated in three hormone-containing growth medium (3H, containing thyroid-stimulating hormone, insulin, and serum) as described previously (10). Cells were rendered quiescent by starvation in Coon's modified Ham's F-12 medium devoid of thyroid-stimulating hormone and growth factors (basal medium) for 48–72 h.

Adenoviral Infection—Adenoviruses for PKC{alpha}, -{delta} (2, 3), and -{epsilon} and kinase-defective PKC{delta}(K376R) (11) were used. Quiescent cells were infected with adenoviruses for PKC{alpha} (2,000 or 10,000 particles (p)/cell), PKC{delta} (5,000 p/cell), or PKC{epsilon} (7,000 p/cell) in basal medium for 16 h (day 1 post-infection). Virus was removed, and the cells washed twice and incubated in basal medium for the times indicated. In experiments where TPA was used, TPA (25 nM) was added at day 2 post-infection for 60 min, and the cells were washed and then incubated in basal medium for the times indicated. Inhibitors were added at the time of infection and again at day 1 post-infection.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 1.
PKC{delta} stimulates cell cycle progression in quiescent thyroid cells. A, upper panel, cells were infected with PKC{alpha} (10,000 particles (p)/cell), PKC{delta} (5,000 p/cell), or PKC{epsilon} (7,000 p/cell) (see "Experimental Procedures") and harvested at days 3–5 post-infection (gray bars). Floating and adherent cells were collected and analyzed for cell cycle position by FACS analysis. Control (open bars) represents mock infected cells. Where indicated, TPA was used on day 2 post-infection (black bars) as described under "Experimental Procedures." Results show one of three complete time-course experiments performed (two full time-course experiments were performed with PKC{delta} plus TPA). Similar results with PKC{delta} (minus TPA) on days 2–4 have been observed in more than six experiments. Lower panel, parental cells were stimulated with TPA (25 nM) for 60 min, washed, and incubated in basal medium for 24, 48, and 72 h. TPA failed to stimulate cell cycle progression in parental cells. Two experiments were performed with similar results. B, cells were infected as described above and harvested at day 2 post-infection, and kinase activity was assessed using PKC{alpha}-pseudosubstrate peptide as substrate (12). The results of a representative experiment performed in triplicate are shown. Similar results were observed in three independent experiments. C, cells infected as described above were harvested at day 2, and PKC expression was assessed by Western blotting with PKC{alpha}, -{delta}, and -{epsilon}-specific antibodies.

 
Flow Cytometry—Floating and trypsinized cells were collected and pelleted at 1,000 rpm for 5 min at 4 °C. Cells were fixed in ice-cold MeOH overnight and resuspended in 250 µl each RNase (200 units/ml) and propidium iodide (0.1 mg/ml in 0.1% Triton X-100, 0.037 mg/ml EDTA) in phosphate-buffered saline. Cells were analyzed on a BD Biosciences FACScan and analyzed using CellQuestTM Pro software.

DNA Laddering—Floating and adherent cells were collected and resuspended in TE/Triton buffer (0.2% Triton X-100, 10 mM Tris, pH 8.0, 1 mM EDTA). Following incubation on ice for 10 min, an aliquot of the lysate containing total DNA was removed, and the remaining lysate was centrifuged at 14,000 x g for 15 min at 4 °C. Supernatant containing low molecular weight DNA was transferred to a fresh tube and treated with DNase-free RNase A (60 µg/ml) for 1 h at 37°C. SDS (0.5%) and proteinase K (150 µg/ml) were added, and the samples were incubated for 1 h at 50 °C.DNAwas precipitated by addition of 0.1 volume of 0.5 M NaCl and 1.0 volume isopropanol, followed by incubation on ice for 10 min. Following centrifugation, DNA was resuspended in TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA) and fractionated on 2% agarose gels.

Immunostaining—DNA synthesis was assessed by BrdUrd incorporation as described in Kupperman et al. (10). For active caspase-3 and {gamma}-H2AX staining, cells were fixed in 3.7% formaldehyde/phosphate-buffered saline, permeabilized in 0.2% Triton X-100 for 2 min, and stained with primary and secondary antibodies for 1 h at 37 °C. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Images were captured on a Zeiss Axiophot microscope fitted with a Hamamatsu ORCA-ER digital camera using Axiovision 4.2 software.

Western Blotting—Cells were washed in ice-cold phosphate-buffered saline and lysed in radioimmune precipitation assay buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS) plus protease inhibitors. Protein content in clarified lysates was assayed using the Bio-Rad DC protein assay. Incubations with primary antibodies were performed overnight at 4 °C, followed by incubation with horseradish peroxidase-conjugated secondary antibodies and detection via chemiluminescence.

Kinase Assays—For PKC assays, infected cells were scraped in isotonic buffer (50 mM Tris, pH 7.4) containing protease inhibitors, sonicated, and clarified by centrifugation. Protein concentration was determined, and samples were dispensed into 20-µl aliquots in triplicate. 30 µl of kinase reaction buffer (50 mM Tris, pH 7.4, 1 mM EGTA, 25 µM ATP, 7.5 mM MgAc, 10 µM PKC{alpha} pseudosubstrate peptide (12), 100 µg/ml phosphatidylserine, 1 µCi/sample [{gamma}-32P]ATP, 1 µM TPA) was added, and the samples were incubated for 10 min at 30 °C. Reactions were terminated by spotting 25 µl of reaction mixture onto Whatman PE-81 paper. Papers were washed in 0.1 M phosphoric acid, rinsed in acetone, and air dried prior to counting. Results are presented as counts per min (CPM)/µg of protein. For Cdk-2 assays, Cdk-2 was immunoprecipitated (Cdk-2 (M2) goat, Santa Cruz Biotechnology), washed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 2.5 mM EGTA, 1 mM NaF, 1 mM {beta}-glycerophosphate) containing protease inhibitors, followed by kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl, 1 mM dithiothreitol) and in vitro kinase assays performed as described in Lewis et al. (13) using histone H1 as substrate.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 2.
Effects of PKC{delta} on cell cycle regulators. A, total cell lysates prepared from PKC{delta}-infected cells at days 1–4 post-infection were subjected to Western blotting using antibodies directed to cyclins A, E, and B1 or Cdk-2. Control (–) represents mock infected quiescent cells. 3H represents quiescent cells stimulated with growth medium for 30 h as a positive control for cyclin B1 expression. Three experiments were performed with similar results. B, Cdk-2 was immunoprecipitated and kinase activity assessed in vitro using histone-H1 as substrate (see "Experimental Procedures"). Two experiments were performed with similar results.

 



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 3.
PKC{delta} induces S phase arrest followed by apoptosis. A, PKC{delta}-infected cells were harvested on days 2–5 post-infection and analyzed by flow cytometry for DNA content. Bar indicates cells with sub-G1 (hypodiploid) DNA content. The arrow indicates the position of S phase cells. The asterisk indicates G2/M phase cells. Two time-course experiments (days 2–5) were performed with similar results. B, PKC{delta}-infected cells were treated with QVD (20 µM) at the time of infection and analyzed by flow cytometry at day 4 post-infection. Three experiments were performed with similar results. C, quiescent parental cells were stimulated with growth medium (3H) for 30 h in the absence or presence of 10 µM nocodazole.

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
PKC{delta} Induces Aberrant Cell Cycle Progression—Phorbol esters stimulate proliferation and impair differentiated function in thyroid epithelial cells. Because differentiated function is an important prognostic indicator for patients with thyroid tumors (14), the identity of the PKC isozymes responsible for these effects is important to ascertain. To elucidate the contributions of PKC{alpha}, -{delta}, and -{epsilon}, the phorbol ester-responsive isozymes expressed in Wistar rat thyroid cells (15), to the regulation of thyroid cell proliferation and function, we utilized adenoviruses to overexpress individual PKC isozymes. Quiescent Wistar rat thyroid cells were infected with adenoviruses expressing PKC{alpha}, -{delta}, or -{epsilon} at varying multiplicities of infection and kinase activity measured in cell lysates prepared at day 2 post-infection. Conditions were derived under which each isozyme exhibited a modest 2-fold increase over endogenous PKC activity, and could be selectively activated with a dose of TPA to which uninfected cells did not respond (2) (Fig. 1B and data not shown). Western blotting indicated that the PKC isozymes were substantially overexpressed under these conditions (Fig. 1C). Immunostaining experiments conducted with PKC-selective antibodies revealed that >95% of the cells were infected under these conditions (data not shown).

Flow cytometry analysis of propidium iodide-stained cells revealed that PKC{delta} selectively induced cell cycle entry. Expression of PKC{delta} decreased the proportion of G1 phase cells and significantly increased the number of S phase cells (Fig. 1A). The effects of PKC{delta} on S phase entry were similar in the presence and absence of TPA activation. Strikingly, the effects of PKC{delta} on cell cycle progression were not reproduced by PKC{alpha} or -{epsilon} even following expression at higher levels than PKC{delta} and in the presence or absence of phorbol ester treatment. At the concentration used, TPA failed to stimulate cell cycle progression in mock infected cells (Fig. 1A, lower panel). To corroborate these data, the effects of PKC{delta} on molecular markers of cell cycle progression were analyzed. PKC{delta} stimulated the expression of cyclins A and E, as well as of Cdk-2, the catalytic partner for the G1 phase cyclins (Fig. 2A). Expression was increased beginning at day 2 post-infection and sustained over 4 days. The up-regulation of cyclins and Cdk-2 was functional, as evidenced by the sustained increase in Cdk-2 activity (Fig. 2B).



View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 4.
PKC{delta} selectively stimulates hypodiploid DNA content. Cells infected with PKC{alpha}, -{delta}, or -{epsilon} (gray bars) were treated with 25 nM TPA for 60 min on day 2 post-infection where indicated (black bars). Cells were fixed on days 3–5 post-infection, stained with propidium iodide, and analyzed for DNA content by flow cytometry. Control (open bars) represents mock infected quiescent cells. One representative time course from three performed with similar results is shown (two full time-course experiments were performed with PKC{delta} plus TPA).

 



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 5.
PKC{delta} stimulates apoptotic cell death. A, lysates prepared from adherent (Ad) and floating (Fl) PKC{delta}-infected cells harvested on day 5 post-infection were subjected to Western blotting using an antibody that detects pro- and cleaved forms of caspase-3. Bar represents mock infected quiescent cells. Two experiments were performed with similar results. In B: Upper panels, PKC{delta}-infected cells harvested at days 1–4 post-infection were stained with an antibody that selectively recognizes cleaved caspase-3 and with DAPI to label all nuclei. Control represents mock infected quiescent cells. Lower panel, in a separate experiment QVD (20 µM) was added at the time of infection, and the cells were stained on day 4 post-infection. All images were collected for equal times. Two experiments were performed with similar results. In C: Upper panel, PKC{delta}-infected cells in the presence or absence of QVD (20 µM) were harvested on day 4 post-infection, and low molecular weight DNA was isolated and fractionated on agarose gels (see "Experimental Procedures"). Lower panel, samples of total DNA were analyzed for each condition to document similar DNA recovery. Bar (first lane) represents DNA isolated from mock infected quiescent cells. Three experiments were performed with similar results.

 
Intriguingly, PKC{delta}-infected cells did not progress into G2/M (Fig. 1A), suggesting that these cells fail to complete the cell cycle. This is most clearly seen in Fig. 3A where PKC{delta} stimulated a time-dependent increase in S phase cells (days 2–3) without a coordinate increase in G2 phase cells (days 2–5). This pattern was strikingly different from that observed following mitogenic (3H) treatment of quiescent cells (Fig. 3C). PKC{delta}-infected cells arrested with a DNA content that was greater than that of G1 phase (3H, 30 h) cells and less than that of G2/M phase (3H plus nocodazole) cells. In agreement with these data, PKC{delta} failed to stimulate cyclin B1 expression, a marker of G2 phase cells (Fig. 2A). Together, these results indicate that a modest increase in PKC{delta} activity is sufficient to induce exit from quiescence, but not to stimulate cell proliferation. Rather, PKC{delta}-expressing cells proceed through G1 phase and subsequently arrest in S phase.

PKC{delta}-stimulated S Phase Arrest Is Followed by Apoptosis—The proportion of PKC{delta}-infected S phase cells declined over time, commensurate with an increase in the proportion of cells containing hypodiploid DNA (Figs. 3A and 4). Despite their similar activities, PKC{alpha} and -{epsilon} did not stimulate hypodiploid DNA content in the presence or absence of TPA activation (Fig. 4). Similar to its effects on cell cycle progression, hypodiploid DNA content induced by PKC{delta} did not require TPA activation.

To document that the effects of PKC{delta} on hypodiploid DNA content reflected apoptosis, caspase-3 cleavage was examined. Western blotting using an antibody that detects pro-caspase-3 and activated (cleaved) forms of caspase-3 revealed the presence of cleaved caspase-3 in lysates prepared from detached (floating) PKC{delta}-infected cells (Fig. 5A). The abundance of intact pro-caspase-3 was markedly reduced in these cells. Longer exposures of the Western blot shown in Fig. 5A revealed the presence of cleaved caspase-3 in adherent cells (data not shown), indicating that cleavage was not secondary to cell detachment. Nonetheless, to confirm that apoptosis was initiated in adherent cells, we analyzed the expression of active caspase-3 using an antibody that selectively recognizes the cleaved form of caspase-3. Staining for active caspase-3 was first detected at day 3 post-infection and increased over time (Fig. 5B). The caspase-3 positive cells invariably exhibited an apoptotic nuclear morphology assessed by DAPI staining. Active caspase-3 staining was abolished following treatment with the pancaspase inhibitor Q-VD-OPh (QVD) (Fig. 5B). Finally, PKC{delta} stimulated QVD-sensitive DNA laddering, confirming that cell death was apoptotic (Fig. 5C).

PKC{delta} is subject to caspase-dependent cleavage, generating a C-terminal fragment containing an intact kinase domain (16). DeVries et al. (17) reported that overexpression of the PKC{delta} fragment resulted in its accumulation in the nucleus and the induction of apoptosis. Western blotting with a C-terminal-directed antibody failed to reveal the presence of significant amounts of the PKC{delta} fragment in apoptotic thyroid cells (data not shown), hence we do not believe PKC{delta} cleavage initiates apoptosis in these cells.

Given that apoptosis temporally follows the accumulation of cells in S phase, we reasoned that PKC{delta}-infected cells die from S phase. Indeed, inhibition of apoptosis with QVD prevented the accumulation of cells with hypodiploid DNA and markedly increased the proportion of S phase cells (Fig. 3B). This result, together with the absence of cyclin B1 expression as well as of G2/M phase cells (Figs. 1 and 2), strongly suggests that expression of PKC{delta} stimulates S phase arrest that culminates in apoptosis.

PKC{delta} Activates the DNA Damage Response Pathway—We set out to confirm the effects of PKC{delta} on S phase entry by monitoring effects on DNA synthesis. DNA synthesis was examined by incorporation of the thymidine analog bromodeoxyuridine (BrdUrd) into replicating DNA (10). Unlike mitogen-treated thyroid cells where BrdUrd labeling is uniform (13, 18, 19), BrdUrd localized to punctate foci in PKC{delta}-infected cells (Fig. 6A). The significance of these foci remains to be determined; however, they are reminiscent of the foci observed following stalled replication and/or DNA damage (20, 21). This prompted us to investigate whether PKC{delta} activated the DNA damage response pathway.

ATR-, ATM-, and DNA-dependent protein kinase (DNA-PK) are key mediators of the cellular response to DNA damage. These PI3K-like kinases are activated by replication stress and DNA double strand breaks. Activation of ATR/ATM results in the phosphorylation and activation of downstream substrates, notably Chk-1 and Chk-2. Stalled replication is a robust stimulator of ATR activity and culminates in the activating phosphorylation of Chk-1 on serine 345 (22). Overexpression of PKC{delta}, but not PKC{alpha}, stimulated Chk-1 phosphorylation (Fig. 6B). Phosphorylation was maximal at day 2 post-infection, similar to the time course over which PKC{delta} stimulated DNA synthesis (data not shown). To confirm the activation of cell cycle checkpoints, the effects of PKC{delta} on p53 phosphorylation were examined. ATR and ATM phosphorylate p53 on serine 15 (23). PKC{delta} stimulated p53 phosphorylation at this site, whereas PKC{alpha} failed to do so (Fig. 6C). Phosphorylation of p53 in PKC{delta}-expressing cells was maximal at day 2 post-infection with significant phosphorylation also observed at day 3. To further document checkpoint activation, we assessed the effects of PKC{delta} on the phosphorylation of histone H2AX (designated {gamma}-H2AX), an indicator of DNA double strand breaks (24). Immunostaining experiments revealed an increase in {gamma}-H2AX staining as early as day 2 post-infection (Fig. 6D). Thus, {gamma}-H2AX staining temporally coincided with BrdUrd incorporation and Chk-1 and p53 phosphorylation. In contrast, caspase-3 activation was first detected at day 3 post-infection (Fig. 5B), suggesting that it followed checkpoint activation. To eliminate the possibility that DNA cleavage itself induced checkpoint activation, the effects of PKC{delta} on checkpoint activity were examined in the presence of the caspase inhibitor QVD. QVD had no effect on the ability of PKC{delta} to stimulate Chk-1, p53, or H2AX phosphorylation (Fig. 6, B and C, and data not shown). These data support a model wherein PKC{delta} stimulates replication stress, leading to checkpoint activation and ultimately, apoptosis.

PKC{delta}-stimulated Apoptosis Requires Cell Cycle Entry—PKC{delta} has been reported to activate JNK (25, 26) and to require p38 or ERK for induction of apoptosis (4, 27). Pharmacological inhibitors of JNK (SP600125), p38 (SB203580), and MEK1 (UO126) were used to determine whether PKC{delta}-stimulated apoptosis requires activity of these MAPK family members. None of these inhibitors impaired DNA laddering induced by PKC{delta} (Fig. 7A). Intriguingly, treatment with the pan-PKC inhibitor GF109203X also failed to impair DNA laddering. To further examine whether kinase activity was required for PKC{delta}-stimulated apoptosis, the effects of kinase-deficient PKC{delta} were examined. Following expression at levels similar to wild type PKC{delta} (data not shown), kinase-deficient PKC{delta} stimulated apoptosis as assessed by hypodiploid DNA content (Fig. 7B). Therefore, kinase activity is not strictly required for the effects of PKC{delta} on apoptosis in thyroid cells. Indeed, kinase-dependent and -independent effects of PKC{delta} on apoptosis have been previously reported (28, 29).



View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 6.
PKC{delta} activates cell cycle checkpoints. A, PKC{delta}-infected cells were pulse-labeled with BrdUrd for 4 h on day 2 post-infection, fixed, and stained for BrdUrd incorporation and with DAPI. Control represents mock infected quiescent cells (<1% BrdUrd-positive cells). A field of quiescent cells harboring a BrdUrd-positive cell was selected to illustrate typical BrdUrd staining. Three independent experiments were performed. In B: Upper panels, lysates prepared from PKC{delta}-infected cells harvested at days 1–3 post-infection were subjected to Western blotting with antibody directed to p-Chk1(Ser-345). The same blot was probed with actin to demonstrate equal loading. Two time-course experiments were performed with similar results. PKC{delta} was observed to phosphorylate Chk-1 at day 2 in more than five experiments. Lower panels, lysates prepared from PKC{delta}- and PKC{alpha}-(10,000 p/cell) infected cells harvested at day 2 were subjected to Western blotting with the p-Chk1(Ser-345) antibody. Pretreatment with QVD (20 µM) had no effect on Chk-1 phosphorylation in response to PKC{delta}. The same blot was probed with an anti-actin antibody to document equal protein loading. Two experiments were performed with similar results for PKC{alpha} and four experiments for QVD on PKC{delta} effects. In C: Upper panels, total cell lysates prepared from PKC{delta}-infected cells on days 2–3 post-infection were subjected to Western blotting with antibodies to p-p53 (Ser-15) and actin. Three experiments were performed with similar results. Lower panels, Western blot of total cell lysates prepared from PKC{delta}- and PKC{alpha} (10K p/cell)-infected cells harvested at day 2 post-infection in the presence or absence of QVD (20 µM) and probed for p-p53 (Ser-15) and actin. Two experiments were performed with similar results for PKC{alpha}, and four experiments for QVD on PKC{delta} effects. D, PKC{delta}-infected cells were fixed at day 2 post-infection and stained with an antibody detecting histone H2AX phosphorylated at Ser-139 ({gamma}-H2AX) and with DAPI. Images were exposed for equal times. Three experiments were performed with similar results.

 
Given that apoptosis temporally follows a delay in S phase, we set out to determine whether inhibition of cell cycle entry would prevent apoptosis. Phosphatidylinositol 3-kinase (PI3K) activity is required for thyroid cell proliferation (19). Therefore, the PI3K inhibitor LY294002 was used to investigate the consequences of cell cycle inhibition on PKC{delta}-stimulated apoptosis. Unlike the other inhibitors tested, LY294002 abolished DNA laddering (Fig. 7A). FACS analysis confirmed that LY294002 blocked the accumulation of cells containing hypodiploid DNA and that this inhibitor prevented S phase entry (Fig. 7C). Consistent with the latter effect, LY294002 abolished DNA synthesis in PKC{delta}-expressing cells (Fig. 7D). PDK-1 phosphorylates PKC{delta} on T505, a modification that increases kinase activity. Because PDK-1 is downstream of PI3K, we considered the possibility that LY294002 inhibited PKC{delta} kinase activity. Pretreatment of PKC{delta}-infected cells with LY294002 (data not shown), or addition of LY294002 directly to in vitro kinase assays, did not impair PKC{delta} kinase activity (Fig. 7E). Additionally, LY294002 had no effect on PKC{delta} expression (Fig. 8A). Therefore, we speculate that the inhibitory effects of LY294002 on apoptosis are mediated predominantly through its ability to block S phase entry. In agreement with this notion, the JNK, MEK1, and p38 inhibitors were less effective than LY294002 in preventing S phase entry (Fig. 7C) and DNA synthesis (Fig. 7D). The PKC inhibitor GF109203X only partially reduced PKC{delta}-stimulated DNA synthesis.



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 7.
Cell cycle entry is required for PKC{delta}-induced apoptosis. A, low molecular weight DNA was isolated from PKC{delta}-infected cells at day 4 post-infection. Inhibitors (SB203580, SP600125, and UO126 at 10 µM, LY294002 at 15 µM, and GF109203X 5 µM) were added at the time of infection. Basal represents mock infected quiescent cells. The lower panel shows an aliquot of total DNA prepared from each sample. Two to three experiments were performed for each inhibitor. B, cells infected with wild-type or kinase-deficient PKC{delta} were harvested at day 3–5 post-infection and subjected to FACS analysis for hypodiploid DNA content. Kinase-deficient (KD)-PKC{delta} stimulated apoptosis to a similar extent as did WT-PKC{delta}. Results shown are summarized from three experiments. C, PKC{delta}-infected cells were harvested on day 4 post-infection and analyzed for DNA content by FACS analysis. Inhibitors were used as described in A. Two experiments were performed for each inhibitor. D, PKC{delta}-infected cells were pulse-labeled with BrdUrd for 4 h on day 2 post-infection. Inhibitors were added as described in A. Three to four experiments were performed for each inhibitor. E, PKC{delta} kinase activity was examined (as in Fig. 1B) in the presence and absence of 15 µM LY294002. LY failed to inhibit PKC activity in parental (control) cells or in cells overexpressing PKC{delta}. As expected, the pan-PKC inhibitor GF109203X (1 µM) impaired kinase activity. Two experiments (triplicates for each sample) were performed.

 
To further establish that checkpoint activation arose as a consequence of delayed progress through S phase, the effects of LY294002 on PKC{delta}-stimulated Chk-1 and p53 phosphorylation were investigated. Interestingly, treatment with PI3K (LY294002), MEK1 (UO126), p38 (SB203580), or JNK (SP600125) inhibitors blocked or significantly impaired Chk-1 phosphorylation (Fig. 8A). However, these inhibitors differed in their ability to block PKC{delta}-induced p53 phosphorylation. Only the PI3K inhibitor (LY294002) completely inhibited p53 phosphorylation. Because LY294002 is known to inhibit ATR, ATM, and DNA-PK activity (30–33) its effects on Chk-1 phosphorylation were assessed. In contrast to its effects on PKC{delta}-stimulated Chk-1 phosphorylation, LY294002 failed to inhibit Chk-1 phosphorylation in response to aphidicolon (an inhibitor of replication, and positive control for ATR activation/Chk-1 phosphorylation) (Fig. 8B). Therefore, at the concentration used in these studies, LY294002 does not directly inhibit ATR activity. Cumulatively, these data suggest that replication stress in response to PKC{delta} expression initiates a checkpoint response that results in apoptosis (Fig. 9).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 8.
LY294002 blocks checkpoint activation by PKC{delta}. A, PKC{delta}-infected cells were left untreated or treated with LY294002, UO126, SB203580, SP600125, or QVD as described in legend to Fig. 7. Cells were harvested on day 2 post-infection and subjected to Western blotting for p-Chk1 (Ser-345), p-p53 (Ser-15), PKC{delta}, and actin. The inhibitors had no effect on PKC{delta} expression. Greater than five experiments were performed in which LY294002 effects on phosphorylation of Chk-1 were observed. Three experiments were performed with the inhibitors UO126, SB203580, SP600125, and QVD. B, quiescent (bar) Wistar rat thyroid cells were stimulated with 3H growth medium (22 h) followed by treatment with aphidicolin (10 µM, 1 h). Where indicated, LY294002 (15 µM) was added 1 h prior to aphidicolin. Lysates were subjected to Western blot analysis with antibodies to pChk-1 (Ser-345) and actin. Two experiments were performed with similar results.

 



View larger version (6K):
[in this window]
[in a new window]
  		FIGURE 9.
Model for PKC{delta}-stimulated apoptosis. PKC{delta} stimulates entry into S phase, followed by S phase arrest, checkpoint activation, and apoptosis. S phase entry was inhibited by LY294002, suggesting that PI3K is required for the effects of PKC{delta} on G1 to S phase cell cycle progression. Blockade of S phase entry using LY294002 prevented checkpoint activation and apoptosis. The pan-caspase inhibitor QVD blocked apoptosis and increased the proportion of S phase cells. Although not shown here, it is possible that additional pathways activated by PKC{delta} contribute to checkpoint activation and apoptosis.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Using adenoviruses to elicit a 2-fold increase in PKC activity, we compared the cellular consequences associated with selective overexpression of PKC{alpha}, -{delta}, and -{epsilon}. Remarkably, overexpression of PKC{delta} in quiescent thyroid epithelial cells was sufficient to stimulate G1/S phase cell cycle progression. Rather than completing the cell cycle, PKC{delta}-expressing cells arrested in S phase, and ultimately perished by caspase-dependent apoptosis. Blockade of apoptosis restored the accumulation of S phase cells, indicating that PKC{delta}-expressing cells perish from S phase. These highly unusual effects of PKC{delta} could not be reproduced by similar or higher levels of PKC{alpha} or PKC{epsilon} activity. These data reveal that increased PKC{delta} activity is sufficient for exit from the quiescent state, but insufficient for completion of the cell cycle.

Experiments to examine the effects of PKC{delta} on DNA synthesis revealed a highly unusual pattern of BrdUrd incorporation in PKC{delta}-infected cells. Rather than the uniform labeling of nuclei observed in mitogen-treated cells, BrdUrd localized to heterogeneous nuclear foci in PKC{delta}-infected cells. The distinct pattern of BrdUrd incorporation, together with the protracted S phase observed in PKC{delta}-infected cells, prompted us to investigate whether PKC{delta} activated cell cycle checkpoints. ATR, ATM, and DNA-PK are activated by DNA damage and replication stress and play an essential role in the maintenance of genomic stability through their ability to halt cell cycle progression and facilitate DNA repair. Under conditions of replication stress or irreparable DNA damage, checkpoint kinases facilitate cell death. Overexpression of PKC{delta}, but not PKC{alpha} stimulated Chk-1 and p53 phosphorylation, indicators of checkpoint activation. PKC{delta}-infected cells also exhibited phosphorylation of histone H2AX, a marker of DNA double strand breaks.

If apoptosis was a direct consequence of replication stress induced by S phase arrest, then inhibition of S phase entry would be expected to rescue PKC{delta}-expressing cells from apoptosis. Indeed, treatment with the PI3K inhibitor LY294002 blocked S phase entry, checkpoint activation, and apoptosis. In contrast, inhibitors of MAPK cascades did not prevent apoptosis. However, MEK1, JNK, and p38 inhibitors were much less effective than the PI3K inhibitor in blocking S phase entry in PKC{delta}-infected thyroid cells. Hence, our data strongly suggest that it is the accumulation of PKC{delta}-expressing cells in S phase that induces apoptosis and that apoptosis is a consequence of replication stress.

Whether checkpoint activation is essential for PKC{delta}-mediated apoptosis remains to be determined. As members of the phosphatidylinositol kinase family, ATM, ATR, and DNA-PK are inhibited by LY294002 (30–33). To ascertain whether LY294002 rescued apoptosis through the direct inhibition of checkpoint kinase activity, its effects on aphidicolin-stimulated Chk-1 phosphorylation were examined. At the concentration used in these studies, LY294002 blocked Chk-1 phosphorylation in response to PKC{delta}, but not that stimulated by aphidicolin. Nonetheless, we cannot exclude a role for other phosphatidylinositol kinases (i.e. ATM or DNA-PK) in the inhibition of apoptosis by LY294002. PKC{delta} associates with and inhibits the activity of DNA-PK (34), raising the possibility that PKC{delta} stimulates S phase entry and coordinately inhibits DNA repair, resulting in the accumulation of single-stranded DNA and checkpoint activation. Full-length PKC{delta} has been found in the nucleus (17), and we observed nuclear staining following overexpression of PKC{delta} in thyroid cells (data not shown). Therefore, PKC{delta} is in the appropriate cellular compartment to elicit effects on DNA synthesis and repair. Complexes containing PKC{delta} and c-abl, a protein-tyrosine kinase activated by oxidative stress and DNA damage, have also been reported (35, 36). PKC{delta} associates with many cellular proteins, including p73{beta} (37), members of the phospholipid scramblase family PSL-1 (38) and PSL-3 (39), lamin B (40), and src family kinases (reviewed in Ref. 41). Complexes between PKC{delta} and mammalian target of rapamycin (mTOR), as well as PI3K, have also been described (42–44). It is possible that PKC{delta}-containing protein complexes elicit functional consequences on DNA repair and apoptosis, either through alterations in protein phosphorylation or through a scaffolding function. If PKC{delta} acts via the latter mechanism, this would explain why PKC{delta}-stimulated apoptosis is independent of PKC{delta} kinase activity in thyroid and other (29) cells.

At first glance, the ability of PKC{delta} to stimulate G1 phase cell cycle progression appears to conflict with numerous reports in the literature that PKC{delta} mediates growth suppression. However, there is increasing evidence that PKC{delta} positively regulates some aspects of cell cycle progression. Kitamura et al. (45) reported that serum stimulated the biphasic activation of PKC{delta} in fibroblasts. The second wave of PKC{delta} activity was temporally correlated with entry into S phase. Overexpression of PKC{delta} enhanced serum-stimulated DNA synthesis, whereas kinase-defective mutants impaired it, effects that were observed in both 3Y1 and NIH3T3 fibroblasts. In a separate study, overexpression of PKC{delta} led to increased E2F promoter activity in 3Y1 fibroblasts (46). Therefore, accumulating evidence supports a conserved role for PKC{delta} in the positive regulation of early events in the cell cycle. Despite its requirement for serum-stimulated DNA synthesis, chronic overexpression of PKC{delta} mediated growth inhibition in 3Y1 cells (45). Similarly, transient expression of PKC{delta} decreased the proportion of M phase cells. In capillary endothelial cells, overexpression of PKC{delta} caused delayed exit from S phase (47), whereas in PKC{delta}-overexpressing CHO cells, treatment with phorbol esters stimulated G2/M arrest (48). Although apoptosis was not reported in these studies, apoptosis is a common end point of stalled cell cycle progression. PKC{delta}-expressing thyroid cells exhibited sustained increases in Cdk-2 expression and activity. This would be expected to result in the stabilization of E2F, an event known to trigger apoptosis. Moreover, replication stress stabilizes E2F via ATM-dependent phosphorylation, and DNA damage leads to the acetylation of E2F1 and its recruitment to apoptotic promoters (49). Together, these data indicate that PKC{delta} is capable of promoting G1 to S phase transition and either inhibits cell cycle progression at a step between S and G2/M phases, or requires additional signals to efficiently complete the cell cycle. The failure of PKC{delta}-overexpressing cells to complete the cell cycle could be due to an imbalance in the level of PKC{delta} activity compared with that of other PKC enzymes or cell cycle regulators.

In conclusion, our findings reveal a novel mechanism through which PKC{delta} stimulates apoptosis. Apoptosis arises as a consequence of inefficient cell cycle progression, culminating in checkpoint activation and apoptosis (Fig. 9). This is likely to be a well conserved mechanism through which PKC{delta} regulates cell survival, given the reports that PKC{delta} regulates not only apoptosis, but also cell cycle progression. The signaling pathways through which PKC{delta} stimulates apoptosis may vary by cell type; however, we suggest that the mediators of PKC{delta} effects on apoptosis are those that convey effects on cell proliferation. In thyroid epithelial cells, it is clear that the targets of PKC{delta} include members of the phosphatidylinositol kinase family, thereby identifying phosphatidylinositol kinases as downstream mediators of PKC{delta} effects. It will be important to investigate whether PKC{delta} plays a role in thyroid-stimulating hormone-driven proliferation, and/or downstream from thyroid oncogenes such as Ras and Ret/PTC given their effects on both cell proliferation and survival (50–54).


   FOOTNOTES
 
* This work was supported by Public Health Service Grant DK-45696 from NIDDK,National Institutes of Health (NIH) and Grant CA-109543 from NCI, NIH (to J. L. M.) and by Grants CA-89202 and CA-92537 from NCI, NIH (to M. G. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Supported by a minority training grant supplement to Grant DK-45696. Back

2 To whom correspondence should be addressed: Dept. of Pharmacology, University ofPennsylvania School of Medicine, Rm. 1251 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6061. Tel.: 215-898-1909; Fax: 215-746-8941; E-mail: meinkoth{at}pharm.med.upenn.edu.

3 The abbreviations used are: PKC, protein kinase C; BrdUrd, bromodeoxyuridine; TPA,12-O-tetradecanoylphorbol 13-acetate; p, particles; DAPI, 4',6-diamidino-2-phenylindole; JNK, c-Jun NH2-terminal kinase; QVD, Q-VD-OPh; ATR, ATM and Rad3-related; DNA-PK, DNA-dependent protein kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal-regulated kinase kinase; PI3K, phosphatidylinositol 3-kinase; FACS, fluorescence-activated cell sorting. Back


   ACKNOWLEDGMENTS
 
We acknowledge Gregory Prendergast for excellent technical assistance and Melissa Dowling for assistance with FACS.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kazanietz, M. G., Caloca, M. J., Eroles, P., Fujii, T., Garcia-Bermejo, M. L., Reilly, M., and Wang, H. (2000) Biochem. Pharmacol. 60, 1417–1424[CrossRef][Medline] [Order article via Infotrieve]
  2. Fujii, T., Garcia-Bermejo, M. L., Bernabo, J. L., Caamano, J., Ohba, M., Kuroki, T., Li, L., Yuspa, S. H., and Kazanietz, M. G. (2000) J. Biol. Chem. 275, 7574–7582[Abstract/Free Full Text]
  3. Garcia-Bermejo, M. L., Leskow, F. C., Fujii, T., Wang, Q., Blumberg, P. M., Ohba, M., Kuroki, T., Han, K. C., Lee, J., Marquez, V. E., and Kazanietz, M. G. (2002) J. Biol. Chem. 277, 645–655[Abstract/Free Full Text]
  4. Tanaka, Y., Gavrielides, M. V., Mitsuuchi, Y., Fujii, T., and Kazanietz, M. G. (2003) J. Biol. Chem. 278, 33753–33762[Abstract/Free Full Text]
  5. Knauf, J. A., Elisei, R., Mochly-Rosen, D., Liron, T., Chen, X. N., Gonsky, R., Korenberg, J. R., and Fagin, J. A. (1999) J. Biol. Chem. 274, 23414–23425[Abstract/Free Full Text]
  6. Knauf, J. A., Ward, L. S., Nikiforov, Y. E., Nikiforova, M., Puxeddu, E., Medvedovic, M., Liron, T., Mochly-Rosen, D., and Fagin, J. A. (2002) J. Clin. Endocrinol. Metab. 87, 2150–2159[Abstract/Free Full Text]
  7. Hatada, T., Sakanoue, Y., Kusunoki, M., Kobayashi, A., and Utsunomiya, J. (1992) Cancer 70, 2918–2922[CrossRef][Medline] [Order article via Infotrieve]
  8. Kobayashi, K., Shaver, J. K., Liang, W., Siperstein, A. E., Duh, Q. Y., and Clark, O. H. (1993) Thyroid 3, 25–29[Medline] [Order article via Infotrieve]
  9. Prevostel, C., Alvaro, V., de Boisvilliers, F., Martin, A., Jaffiol, C., and Joubert, D. (1995) Oncogene 11, 669–674[Medline] [Order article via Infotrieve]
  10. Kupperman, E., Wofford, D., Wen, W., and Meinkoth, J. L. (1996) Endocrinology 137, 96–104[Abstract]
  11. Li, L., Lorenzo, P. S., Bogi, K., Blumberg, P. M., and Yuspa, S. H. (1999) Mol. Cell Biol. 19, 8547–8558[Abstract/Free Full Text]
  12. Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J. F., and Blumberg, P. M. (1993) Mol. Pharmacol. 44, 298–307[Abstract]
  13. Lewis, A. E., Fikaris, A. J., Prendergast, G. V., and Meinkoth, J. L. (2004) Mol. Endocrinol. 18, 2321–2332[Abstract/Free Full Text]
  14. Sherman, S. I. (2003) Lancet 361, 501–511[CrossRef][Medline] [Order article via Infotrieve]
  15. Fernandez, N., Caloca, M. J., Prendergast, G. V., Meinkoth, J. L., and Kazanietz, M. G. (2000) Endocrinology 141, 146–152[Abstract/Free Full Text]
  16. Reyland, M. E., Anderson, S. M., Matassa, A. A., Barzen, K. A., and Quissell, D. O. (1999) J. Biol. Chem. 274, 19115–19123[Abstract/Free Full Text]
  17. DeVries, T. A., Neville, M. C., and Reyland, M. E. (2002) EMBO J. 21, 6050–6060[CrossRef][Medline] [Order article via Infotrieve]
  18. Tsygankova, O. M., Saavedra, A., Rebhun, J. F., Quilliam, L. A., and Meinkoth, J. L. (2001) Mol. Cell Biol. 21, 1921–1929[Abstract/Free Full Text]
  19. Cass, L. A., Summers, S. A., Prendergast, G. V., Backer, J. M., Birnbaum, M. J., and Meinkoth, J. L. (1999) Mol. Cell Biol. 19, 5882–5891[Abstract/Free Full Text]
  20. Sengupta, S., Linke, S. P., Pedeux, R., Yang, Q., Farnsworth, J., Garfield, S. H., Valerie, K., Shay, J. W., Ellis, N. A., Wasylyk, B., and Harris, C. C. (2003) EMBO J. 22, 1210–1222[CrossRef][Medline] [Order article via Infotrieve]
  21. Dimitrova, D. S., and Gilbert, D. M. (2000) Nat. Cell Biol. 2, 686–694[CrossRef][Medline] [Order article via Infotrieve]
  22. Zhao, H., and Piwnica-Worms, H. (2001) Mol. Cell Biol. 21, 4129–4139[Abstract/Free Full Text]
  23. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K., and Linn, S. (2004) Annu. Rev. Biochem. 73, 39–85[CrossRef][Medline] [Order article via Infotrieve]
  24. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) J. Biol. Chem. 273, 5858–5868[Abstract/Free Full Text]
  25. Reyland, M. E., Barzen, K. A., Anderson, S. M., Quissell, D. O., and Matassa, A. A. (2000) Cell Death Differ. 7, 1200–1209[CrossRef][Medline] [Order article via Infotrieve]
  26. Mitsutake, N., Namba, H., Shklyaev, S. S., Tsukazaki, T., Ohtsuru, A., Ohba, M., Kuroki, T., Ayabe, H., and Yamashita, S. (2001) Oncogene 20, 989–996[CrossRef][Medline] [Order article via Infotrieve]
  27. Lee, Y. J., Soh, J. W., Dean, N. M., Cho, C. K., Kim, T. H., Lee, S. J., and Lee, Y. S. (2002) Cell Growth & Differ. 13, 237–246[Abstract/Free Full Text]
  28. Clark, A. S., West, K. A., Blumberg, P. M., and Dennis, P. A. (2003) Cancer Res. 63, 780–786[Abstract/Free Full Text]
  29. Goerke, A., Sakai, N., Gutjahr, E., Schlapkohl, W. A., Mushinski, J. F., Haller, H., Kolch, W., Saito, N., and Mischak, H. (2002) J. Biol. Chem. 277, 32054–32062[Abstract/Free Full Text]
  30. Izzard, R. A., Jackson, S. P., and Smith, G. C. (1999) Cancer Res. 59, 2581–2586[Abstract/Free Full Text]
  31. Rosenzweig, K. E., Youmell, M. B., Palayoor, S. T., and Price, B. D. (1997) Clin. Cancer Res. 3, 1149–1156[Abstract]
  32. Hall-Jackson, C. A., Cross, D. A., Morrice, N., and Smythe, C. (1999) Oncogene 18, 6707–6713[CrossRef][Medline] [Order article via Infotrieve]
  33. Goodarzi, A. A., and Lees-Miller, S. P. (2004) DNA Repair (Amst). 3, 753–767[CrossRef][Medline] [Order article via Infotrieve]
  34. Bharti, A., Kraeft, S. K., Gounder, M., Pandey, P., Jin, S., Yuan, Z. M., Lees-Miller, S. P., Weichselbaum, R., Weaver, D., Chen, L. B., Kufe, D., and Kharbanda, S. (1998) Mol. Cell Biol. 18, 6719–6728[Abstract/Free Full Text]
  35. Yuan, Z. M., Utsugisawa, T., Ishiko, T., Nakada, S., Huang, Y., Kharbanda, S., Weichselbaum, R., and Kufe, D. (1998) Oncogene 16, 1643–1648[CrossRef][Medline] [Order article via Infotrieve]
  36. Sun, X., Wu, F., Datta, R., Kharbanda, S., and Kufe, D. (2000) J. Biol. Chem. 275, 7470–7473[Abstract/Free Full Text]
  37. Ren, J., Datta, R., Shioya, H., Li, Y., Oki, E., Biedermann, V., Bharti, A., and Kufe, D. (2002) J. Biol. Chem. 277, 33758–33765[Abstract/Free Full Text]
  38. Frasch, S. C., Henson, P. M., Kailey, J. M., Richter, D. A., Janes, M. S., Fadok, V. A., and Bratton, D. L. (2000) J. Biol. Chem. 275, 23065–23073[Abstract/Free Full Text]
  39. Liu, J., Chen, J., Dai, Q., and Lee, R. M. (2003) Cancer Res. 63, 1153–1156[Abstract/Free Full Text]
  40. Cross, T., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., and Lord, J. M. (2000) Oncogene 19, 2331–2337[CrossRef][Medline] [Order article via Infotrieve]
  41. Kikkawa, U., Matsuzaki, H., and Yamamoto, T. (2002) J. Biochem. (Tokyo) 132, 831–839[Abstract/Free Full Text]
  42. Ettinger, S. L., Lauener, R. W., and Duronio, V. (1996) J. Biol. Chem. 271, 14514–14518[Abstract/Free Full Text]
  43. Kumar, V., Pandey, P., Sabatini, D., Kumar, M., Majumder, P. K., Bharti, A., Carmichael, G., Kufe, D., and Kharbanda, S. (2000) EMBO J. 19, 1087–1097[CrossRef][Medline] [Order article via Infotrieve]
  44. Kilpatrick, L. E., Lee, J. Y., Haines, K. M., Campbell, D. E., Sullivan, K. E., and Korchak, H. M. (2002) Am. J. Physiol. 283, C48–C57
  45. Kitamura, K., Mizuno, K., Etoh, A., Akita, Y., Miyamoto, A., Nakayama, K., and Ohno, S. (2003) Genes Cells 8, 311–324[Abstract]
  46. Nakaigawa, N., Hirai, S., Mizuno, K., Shuin, T., Hosaka, M., and Ohno, S. (1996) Biochem. Biophys. Res. Commun. 222, 95–100[CrossRef][Medline] [Order article via Infotrieve]
  47. Harrington, E. O., Loffler, J., Nelson, P. R., Kent, K. C., Simons, M., and Ware, J. A. (1997) J. Biol. Chem. 272, 7390–7397[Abstract/Free Full Text]
  48. Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igarashi, K., Ogita, K., Kikkawa, U., and Nishizuka, Y. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10159–10163[Abstract/Free Full Text]
  49. Ianari, A., Gallo, R., Palma, M., Alesse, E., and Gulino, A. (2004) J. Biol. Chem. 279, 30830–30835[Abstract/Free Full Text]
  50. Cheng, G., and Meinkoth, J. L. (2001) Oncogene 20, 7334–7341[CrossRef][Medline] [Order article via Infotrieve]
  51. Cheng, G., Lewis, A. E., and Meinkoth, J. L. (2003) Mol. Endocrinol. 17, 450–459[Abstract/Free Full Text]
  52. Shirokawa, J. M., Elisei, R., Knauf, J. A., Hara, T., Wang, J., Saavedra, H. I., and Fagin, J. A. (2000) Mol. Endocrinol. 14, 1725–1738[Abstract/Free Full Text]
  53. Castellone, M. D., Cirafici, A. M., De Vita, G., De Falco, V., Malorni, L., Tallini, G., Fagin, J. A., Fusco, A., Melillo, R. M., and Santoro, M. (2003) Oncogene 22, 246–255[CrossRef][Medline] [Order article via Infotrieve]
  54. Wang, J., Knauf, J. A., Basu, S., Puxeddu, E., Kuroda, H., Santoro, M., Fusco, A., and Fagin, J. A. (2003) Mol. Endocrinol. 17, 1425–1436[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Xin, F. Gao, W. S. May, T. Flagg, and X. Deng
Protein Kinase C{zeta} Abrogates the Proapoptotic Function of Bax through Phosphorylation
J. Biol. Chem., July 20, 2007; 282(29): 21268 - 21277.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Xia, L. W. Forman, and D. V. Faller
Protein Kinase C{delta} Is Required for Survival of Cells Expressing Activated p21RAS
J. Biol. Chem., May 4, 2007; 282(18): 13199 - 13210.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M. Gareskog and P. Wentzel
N-Acetylcysteine and {alpha}-cyano-4-hydroxycinnamic acid alter protein kinase C (PKC)-{delta} and PKC-{zeta} and diminish dysmorphogenesis in rat embryos cultured with high glucose in vitro
J. Endocrinol., January 1, 2007; 192(1): 207 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. J. Fikaris, A. E. Lewis, A. Abulaiti, O. M. Tsygankova, and J. L. Meinkoth
Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling
J. Biol. Chem., November 17, 2006; 281(46): 34759 - 34767.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Protein kinase C as a therapeutic target.
Clin. Cancer Res., September 15, 2006; 12(18): 5336 - 5345.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. Yoshida, T. Yamaguchi, H. Shinagawa, N. Taira, K. I. Nakayama, and Y. Miki
Protein Kinase C {delta} Activates Topoisomerase II{alpha} To Induce Apoptotic Cell Death in Response to DNA Damage.
Mol. Cell. Biol., May 1, 2006; 26(9): 3414 - 3431.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Dworet and J. L. Meinkoth
Interference with 3',5'-Cyclic Adenosine Monophosphate Response Element Binding Protein Stimulates Apoptosis through Aberrant Cell Cycle Progression and Checkpoint Activation
Mol. Endocrinol., May 1, 2006; 20(5): 1112 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Kwon, C. A. Marshall, H. Liu, K. L. Pappan, M. S. Remedi, and M. L. McDaniel
Glucose-stimulated DNA Synthesis through Mammalian Target of Rapamycin (mTOR) Is Regulated by KATP Channels: EFFECTS ON CELL CYCLE PROGRESSION IN RODENT ISLETS
J. Biol. Chem., February 10, 2006; 281(6): 3261 - 3267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Vitale, W. W. de Herder, P. M. van Koetsveld, M. Waaijers, W. Schoordijk, E. Croze, A. Colao, S. W.J. Lamberts, and L. J. Hofland
IFN-{beta} Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro
Cancer Res., January 1, 2006; 66(1): 554 - 562.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/37/32107    most recent
M504432200v2
M504432200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santiago-Walker, A. E.
Right arrow Articles by Meinkoth, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santiago-Walker, A. E.
Right arrow Articles by Meinkoth, J. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement